View Item 

Show simple item record

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

dc.contributor.authorMiles, D.
dc.contributor.authorChan, Arlene
dc.contributor.authorDirix, L.
dc.contributor.authorCortés, J.
dc.contributor.authorPivot, X.
dc.contributor.authorTomczak, P.
dc.contributor.authorDelozier, T.
dc.contributor.authorSohn, J.
dc.contributor.authorProvencher, L.
dc.contributor.authorPuglisi, F.
dc.contributor.authorHarbeck, N.
dc.contributor.authorSteger, G.
dc.contributor.authorSchneeweiss, A.
dc.contributor.authorWardley, A.
dc.contributor.authorChlistalla, A.
dc.contributor.authorRomieu, G.
dc.date.accessioned2017-01-30T10:50:49Z
dc.date.available2017-01-30T10:50:49Z
dc.date.created2014-11-19T01:13:19Z
dc.date.issued2010
dc.identifier.citationMiles, D. and Chan, A. and Dirix, L. and Cortés, J. and Pivot, X. and Tomczak, P. and Delozier, T. et al. 2010. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology. 28 (20): pp. 3239-3247.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/6136
dc.publisherAmerican Society of Clinical Oncology
dc.titlePhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
dc.typeJournal Article
dcterms.source.volume28
dcterms.source.number20
dcterms.source.startPage3239
dcterms.source.endPage3247
dcterms.source.issn0732 183X
dcterms.source.titleJournal of Clinical Oncology
curtin.accessStatusFulltext not available


Files in this item

Thumbnail
Name:
203748_33891_2010_J.-Clin.-Onc ...
Size:
3.028Kb
Format:
Unknown

This item appears in the following Collection(s)

Show simple item record